• Medacta cut its FY 2026 revenue growth forecast to around 9% in constant currency from 10%-14%.
• Adjusted EBITDA margin now expected broadly flat versus 2025 in constant currency, replacing forecast expansion of approximately 50 basis points.
• The downgrade reflects softer US healthcare conditions, with an expected second-half recovery failing to materialize despite strong customer conversion rates.
• The 2024-2027 revenue growth outlook remains unchanged at a compound annual rate of 12%-15% in constant currency.
• Midterm adjusted EBITDA margin guidance also remains unchanged, targeting gradual improvement from 2025 in constant currency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medacta Group SA published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2429478_en) on November 05, 2026, and is solely responsible for the information contained therein.